» Articles » PMID: 34620087

Intracranial Pressure Directly Predicts Headache morbidity in Idiopathic Intracranial Hypertension

Overview
Journal J Headache Pain
Publisher Biomed Central
Date 2021 Oct 8
PMID 34620087
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Headache is the predominant disabler in idiopathic intracranial hypertension (IIH). The aim was to characterise headache and investigate the association with intracranial pressure.

Methods: IIH:WT was a randomised controlled parallel group multicentre trial in the United Kingdom investigating weight management methods in IIH. Participants with active IIH (evidenced by papilloedema) and a body mass index (BMI) ≥35 kg/m were recruited. At baseline, 12 months and 24 months headache characteristics and quality of life outcome measures were collected and lumbar puncture measurements were performed.

Results: Sixty-six women with active IIH were included with a mean age of 32.0 years (SD ± 7.8), and mean body mass index of 43.9 ± 7.0 kg/m. The headache phenotype was migraine-like in 90%. Headache severity correlated with ICP at baseline (r = 0.285; p = 0.024); change in headache severity and monthly headache days correlated with change in ICP at 12 months (r = 0.454, p = 0.001 and r = 0.419, p = 0.002 respectively). Cutaneous allodynia was significantly correlated with ICP at 12 months. (r = 0.479, p < 0.001). Boot strap analysis noted a positive association between ICP at 12 and 24 months and enabled prediction of both change in headache severity and monthly headache days. ICP was associated with significant improvements in quality of life (SF-36).

Conclusions: We demonstrate a positive relationship between ICP and headache and cutaneous allodynia, which has not been previously reported in IIH. Those with the greatest reduction in ICP over 12 months had the greatest reduction in headache frequency and severity; this was associated with improvement of quality of life measures.

Trial Registration: This work provides Class IIa evidence of the association of raised intracranial pressure and headache. ClinicalTrials.gov number, NCT02124486 .

Citing Articles

Non-invasive assessment of intracranial compliance in idiopathic intracranial hypertension: an MRI-ICP study.

Sassani M, Mitchell J, Yiangou A, Davies N, Sawlani V, Mollan S Eye (Lond). 2025; .

PMID: 39856425 DOI: 10.1038/s41433-024-03547-7.


Does a Healthy Weight Body Mass Index at Onset of Idiopathic Intracranial Hypertension Change the Outcomes? A United Kingdom Prospective Cohort Study.

Thaller M, Homer V, Abbott S, Hazlehurst J, Mollan S, Sinclair A Neuroophthalmology. 2024; 48(6):429-440.

PMID: 39583019 PMC: 11581159. DOI: 10.1080/01658107.2024.2341775.


An interdisciplinary integrated specialized one-stop outpatient clinic for idiopathic intracranial hypertension-a comprehensive assessment of clinical outcome.

Bsteh G, Macher S, Krajnc N, Marik W, Michl M, Muller N Eur J Neurol. 2024; 31(10):e16401.

PMID: 39152571 PMC: 11414812. DOI: 10.1111/ene.16401.


Progress and recognition of idiopathic intracranial hypertension: A narrative review.

Zhou C, Zhou Y, Liu L, Jiang H, Wei H, Zhou C CNS Neurosci Ther. 2024; 30(8):e14895.

PMID: 39097911 PMC: 11298205. DOI: 10.1111/cns.14895.


Managing idiopathic intracranial hypertension in the eye clinic.

Bonelli L, Menon V, Arnold A, Mollan S Eye (Lond). 2024; 38(12):2472-2481.

PMID: 38789788 PMC: 11306398. DOI: 10.1038/s41433-024-03140-y.


References
1.
Yiangou A, Mitchell J, Fisher C, Edwards J, Vijay V, Alimajstorovic Z . Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation. Headache. 2020; 61(1):157-169. PMC: 7898289. DOI: 10.1111/head.14026. View

2.
Hjermstad M, Fayers P, Haugen D, Caraceni A, Hanks G, Loge J . Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011; 41(6):1073-93. DOI: 10.1016/j.jpainsymman.2010.08.016. View

3.
Kristoffersen E, Lundqvist C . Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014; 5(2):87-99. PMC: 4110872. DOI: 10.1177/2042098614522683. View

4.
Mollan S, Davies B, Silver N, Shaw S, Mallucci C, Wakerley B . Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018; 89(10):1088-1100. PMC: 6166610. DOI: 10.1136/jnnp-2017-317440. View

5.
Thaller M, Tsermoulas G, Sun R, Mollan S, Sinclair A . Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2020; 92(7):795-797. PMC: 8223635. DOI: 10.1136/jnnp-2020-325519. View